Details for: TYROBP
Gene ID: 7305
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: TYROBP
Ensembl ID: ENSG00000011600
Description: transmembrane immune signaling adaptor TYROBP
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 104.68rCSI 69.76%PRS 95.67
-
CSI 98.88rCSI 76.18%PRS 93.17
-
CSI 87.94rCSI 80.74%PRS 94.54
-
CSI 81.79rCSI 61.33%PRS 97.6
-
CSI 80.8rCSI 56.41%PRS 93.25
-
CSI 63.43rCSI 76.61%PRS 94.7
-
CSI 63.32rCSI 71.27%PRS 96.93
-
CSI 62.78rCSI 57.92%PRS 91.44
-
CSI 62.19rCSI 78.18%PRS 95.28
-
CSI 60.44rCSI 79.2%PRS 95.95
-
CSI 59.8rCSI 74.48%PRS 95.44
-
CSI 47.38rCSI 70.24%PRS 94.89
-
CSI 46.89rCSI 75.16%PRS 94.83
-
CSI 45.91rCSI 75.61%PRS 92.06
-
CSI 43.47rCSI 74.47%PRS 92.33
-
CSI 43.15rCSI 65.11%PRS 94.04
-
CSI 42.65rCSI 52.54%PRS 89.99
-
CSI 39.75rCSI 61.05%PRS 95.34
-
CSI 39.03rCSI 56.54%PRS 97.08
-
CSI 38.52rCSI 72.72%PRS 94.77
-
CSI 38.42rCSI 33.27%PRS 92.28
-
CSI 36.94rCSI 56.42%PRS 95.79
-
CSI 36.33rCSI 42.67%PRS 95.45
-
CSI 35.94rCSI 61.42%PRS 97.19
-
CSI 35.67rCSI 36.13%PRS 95.78
-
CSI 35.22rCSI 29.4%PRS 85.3
-
CSI 33.99rCSI 61.84%PRS 90.89
-
CSI 32.34rCSI 58.45%PRS 91.49
-
CSI 32.12rCSI 71.75%PRS 94.48
-
CSI 31.69rCSI 69.76%PRS 92.57
-
CSI 31.64rCSI 72.36%PRS 91.36
-
CSI 31.32rCSI 23.83%PRS 97.76
-
CSI 31.05rCSI 31.95%PRS 95.8
-
CSI 30.79rCSI 23.13%PRS 93.55
-
CSI 29.3rCSI 19.74%PRS 97.62
-
CSI 29.19rCSI 37.34%PRS 94.29
-
CSI 28.59rCSI 34.14%PRS 97.55
-
CSI 28.26rCSI 25.74%PRS 97.1
-
CSI 26.99rCSI 28.19%PRS 95.99
-
CSI 26.81rCSI 33.65%PRS 94.92
-
CSI 25.77rCSI 19.28%PRS 96.79
-
CSI 25.36rCSI 16.85%PRS 91.69
-
CSI 24.62rCSI 19.15%PRS 97.14
-
CSI 23.27rCSI 22.87%PRS 96.58
-
CSI 22.41rCSI 60.99%PRS 97.34
-
CSI 22.3rCSI 43.22%PRS 92.7
-
CSI 20.46rCSI 42.23%PRS 84.78
-
CSI 20.34rCSI 83.75%PRS 93.09
-
CSI 19.86rCSI 17.44%PRS 93.23
-
CSI 19.38rCSI 27.95%PRS 92.41
-
CSI 18.31rCSI 27.97%PRS 94.2
-
CSI 17.44rCSI 66.42%PRS 83.74
-
CSI 17.3rCSI 38.83%PRS 96.76
-
CSI 16.79rCSI 35.53%PRS 95.13
-
CSI 16.42rCSI 31.63%PRS 97.79
-
CSI 15.83rCSI 73.11%PRS 96.36
-
CSI 15.57rCSI 35.32%PRS 88.69
-
CSI 14.69rCSI 10.97%PRS 96.3
-
CSI 14.34rCSI 53.72%PRS 85.66
-
CSI 13.55rCSI 12.61%PRS 91.53
-
CSI 13.49rCSI 18.35%PRS 94.54
-
CSI 12.67rCSI 71.3%PRS 96.79
-
CSI 12.53rCSI 75.78%PRS 95.31
-
CSI 12.37rCSI 42.6%PRS 94.12
-
CSI 12.28rCSI 16.88%PRS 97.76
-
CSI 12.08rCSI 26.09%PRS 89.33
-
CSI 11.99rCSI 28.14%PRS 88.06
-
CSI 11.97rCSI 9.28%PRS 92.75
-
CSI 11.21rCSI 9.11%PRS 89.58
-
CSI 10.99rCSI 45.61%PRS 87.04
-
CSI 10.68rCSI 8.4%PRS 92.64
-
CSI 10.23rCSI 26.66%PRS 91.69
-
CSI 10.01rCSI 8.09%PRS 91.5
-
CSI 9.6rCSI 8.41%PRS 94.08
-
CSI 9.19rCSI 8.3%PRS 89.04
-
CSI 9.02rCSI 59.25%PRS 95.78
-
CSI 8.77rCSI 8.75%PRS 84.84
-
CSI 8.36rCSI 33.64%PRS 88.69
-
CSI 7.68rCSI 42.95%PRS 87.78
-
CSI 6.72rCSI 8.98%PRS 97.37
-
CSI 6.62rCSI 4.6%PRS 97.16
-
CSI 6.6rCSI 33.12%PRS 96.9
-
CSI 6.6rCSI 5.74%PRS 95.85
-
CSI 6.55rCSI 66.57%PRS 95.67
-
CSI 6.49rCSI 7.51%PRS 84.86
-
CSI 6.33rCSI 68.88%PRS 95.36
-
CSI 6.04rCSI 5.01%PRS 91.08
-
CSI 5.69rCSI 24.68%PRS 91.69
-
CSI 5.39rCSI 91.29%PRS 93.5
-
CSI 5.39rCSI 8.52%PRS 91.17
-
CSI 5.38rCSI 7.33%PRS 97.92
-
CSI 4.68rCSI 14.41%PRS 92.13
-
CSI 4.38rCSI 11.34%PRS 97.66
-
CSI 4.05rCSI 4.64%PRS 94.23
-
CSI 3.87rCSI 25.36%PRS 96.83
-
CSI 3.81rCSI 17.81%PRS 96.3
-
CSI 3.12rCSI 3.65%PRS 97.13
-
CSI 2.84rCSI 14.01%PRS 93.98
-
CSI 2.83rCSI 14.61%PRS 97.13
-
CSI 2.28rCSI 45.49%PRS 95.89
-
CSI 0.4rCSI 5.0%PRS 97.2%
-
CSI 0.6rCSI 3.1%PRS 92.4%
-
CSI 0.8rCSI 4.5%PRS 97.7%
-
CSI 1.0rCSI 3.3%PRS 97.0%
-
CSI 1.1rCSI 6.5%PRS 89.6%
-
CSI 1.6rCSI 1.9%PRS 71.3%
-
CSI 2.3rCSI 45.5%PRS 95.9%
-
CSI 2.8rCSI 14.6%PRS 97.1%
-
CSI 2.8rCSI 14.0%PRS 94.0%
-
CSI 3.1rCSI 3.7%PRS 97.1%
-
CSI 3.8rCSI 17.8%PRS 96.3%
-
CSI 3.9rCSI 25.4%PRS 96.8%
-
CSI 4.1rCSI 4.6%PRS 94.2%
-
CSI 4.4rCSI 11.3%PRS 97.7%
-
CSI 4.7rCSI 14.4%PRS 92.1%
-
CSI 5.4rCSI 7.3%PRS 97.9%
-
CSI 5.4rCSI 8.5%PRS 91.2%
-
CSI 5.4rCSI 91.3%PRS 93.5%
-
CSI 5.7rCSI 24.7%PRS 91.7%
-
CSI 6.0rCSI 5.0%PRS 91.1%
-
CSI 6.3rCSI 68.9%PRS 95.4%
-
CSI 6.5rCSI 7.5%PRS 84.9%
-
CSI 6.6rCSI 66.6%PRS 95.7%
-
CSI 6.6rCSI 5.7%PRS 95.9%
-
CSI 6.6rCSI 33.1%PRS 96.9%
-
CSI 6.6rCSI 4.6%PRS 97.2%
-
CSI 6.7rCSI 9.0%PRS 97.4%
-
CSI 7.7rCSI 43.0%PRS 87.8%
-
CSI 8.4rCSI 33.6%PRS 88.7%
-
CSI 8.8rCSI 8.8%PRS 84.8%
-
CSI 9.0rCSI 59.3%PRS 95.8%
-
CSI 9.2rCSI 8.3%PRS 89.0%
-
CSI 9.6rCSI 8.4%PRS 94.1%
-
CSI 10.0rCSI 8.1%PRS 91.5%
-
CSI 10.2rCSI 26.7%PRS 91.7%
-
CSI 10.7rCSI 8.4%PRS 92.6%
-
CSI 11.0rCSI 45.6%PRS 87.0%
-
CSI 11.2rCSI 9.1%PRS 89.6%
-
CSI 12.0rCSI 9.3%PRS 92.8%
-
CSI 12.0rCSI 28.1%PRS 88.1%
-
CSI 12.1rCSI 26.1%PRS 89.3%
-
CSI 12.3rCSI 16.9%PRS 97.8%
-
CSI 12.4rCSI 42.6%PRS 94.1%
-
CSI 12.5rCSI 75.8%PRS 95.3%
-
CSI 12.7rCSI 71.3%PRS 96.8%
-
CSI 13.5rCSI 18.4%PRS 94.5%
-
CSI 13.6rCSI 12.6%PRS 91.5%
-
CSI 14.3rCSI 53.7%PRS 85.7%
-
CSI 14.7rCSI 11.0%PRS 96.3%
-
CSI 15.6rCSI 35.3%PRS 88.7%
-
CSI 15.8rCSI 73.1%PRS 96.4%
-
CSI 16.4rCSI 31.6%PRS 97.8%
-
CSI 16.8rCSI 35.5%PRS 95.1%
-
CSI 17.3rCSI 38.8%PRS 96.8%
-
CSI 17.4rCSI 66.4%PRS 83.7%
-
CSI 18.3rCSI 28.0%PRS 94.2%
-
CSI 19.4rCSI 28.0%PRS 92.4%
-
CSI 19.9rCSI 17.4%PRS 93.2%
-
CSI 20.3rCSI 83.8%PRS 93.1%
-
CSI 20.5rCSI 42.2%PRS 84.8%
-
CSI 22.3rCSI 43.2%PRS 92.7%
-
CSI 22.4rCSI 61.0%PRS 97.3%
-
CSI 23.3rCSI 22.9%PRS 96.6%
-
CSI 24.6rCSI 19.2%PRS 97.1%
-
CSI 25.4rCSI 16.9%PRS 91.7%
-
CSI 25.8rCSI 19.3%PRS 96.8%
-
CSI 26.8rCSI 33.7%PRS 94.9%
-
CSI 27.0rCSI 28.2%PRS 96.0%
-
CSI 28.3rCSI 25.7%PRS 97.1%
-
CSI 28.6rCSI 34.1%PRS 97.6%
-
CSI 29.2rCSI 37.3%PRS 94.3%
-
CSI 29.3rCSI 19.7%PRS 97.6%
-
CSI 30.8rCSI 23.1%PRS 93.6%
-
CSI 31.1rCSI 32.0%PRS 95.8%
-
CSI 31.3rCSI 23.8%PRS 97.8%
-
CSI 31.6rCSI 72.4%PRS 91.4%
-
CSI 31.7rCSI 69.8%PRS 92.6%
-
CSI 32.1rCSI 71.8%PRS 94.5%
-
CSI 32.3rCSI 58.5%PRS 91.5%
-
CSI 34.0rCSI 61.8%PRS 90.9%
-
CSI 35.2rCSI 29.4%PRS 85.3%
-
CSI 35.7rCSI 36.1%PRS 95.8%
-
CSI 35.9rCSI 61.4%PRS 97.2%
-
CSI 36.3rCSI 42.7%PRS 95.5%
-
CSI 36.9rCSI 56.4%PRS 95.8%
-
CSI 38.4rCSI 33.3%PRS 92.3%
-
CSI 38.5rCSI 72.7%PRS 94.8%
-
CSI 39.0rCSI 56.5%PRS 97.1%
-
CSI 39.8rCSI 61.1%PRS 95.3%
-
CSI 42.7rCSI 52.5%PRS 90.0%
-
CSI 43.2rCSI 65.1%PRS 94.0%
-
CSI 43.5rCSI 74.5%PRS 92.3%
-
CSI 45.9rCSI 75.6%PRS 92.1%
-
CSI 46.9rCSI 75.2%PRS 94.8%
-
CSI 47.4rCSI 70.2%PRS 94.9%
-
CSI 59.8rCSI 74.5%PRS 95.4%
-
CSI 60.4rCSI 79.2%PRS 96.0%
-
CSI 62.2rCSI 78.2%PRS 95.3%
-
CSI 62.8rCSI 57.9%PRS 91.4%
-
CSI 63.3rCSI 71.3%PRS 96.9%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 3786314690
Symbol: TYOBP_HUMAN
Name: Killer-activating receptor-associated protein
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 9490415
Title: Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells.
PubMed ID: 9490415
DOI: 10.1038/35642
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 16344560
Title: Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.
PubMed ID: 16344560
DOI: 10.1101/gr.4039406
PubMed ID: 15057824
Title: The DNA sequence and biology of human chromosome 19.
PubMed ID: 15057824
DOI: 10.1038/nature02399
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 9655483
Title: Association of DAP12 with activating CD94/NKG2C NK cell receptors.
PubMed ID: 9655483
PubMed ID: 10449773
Title: Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells.
PubMed ID: 10449773
PubMed ID: 10604985
Title: Signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells.
PubMed ID: 10604985
PubMed ID: 10888890
Title: Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts.
PubMed ID: 10888890
DOI: 10.1038/77153
PubMed ID: 10799849
Title: Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes.
PubMed ID: 10799849
PubMed ID: 11602640
Title: A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells.
PubMed ID: 11602640
PubMed ID: 12370476
Title: Heterogeneity of presenile dementia with bone cysts (Nasu-Hakola disease): three genetic forms.
PubMed ID: 12370476
PubMed ID: 11922939
Title: TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development.
PubMed ID: 11922939
PubMed ID: 15557162
Title: Molecular characterization of a novel immune receptor restricted to the monocytic lineage.
PubMed ID: 15557162
PubMed ID: 15940674
Title: The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells.
PubMed ID: 15940674
PubMed ID: 17012248
Title: Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates.
PubMed ID: 17012248
PubMed ID: 16920917
Title: Molecular and functional characterization of CD300b, a new activating immunoglobulin receptor able to transduce signals through two different pathways.
PubMed ID: 16920917
PubMed ID: 17928527
Title: Analysis of mouse LMIR5/CLM-7 as an activating receptor: differential regulation of LMIR5/CLM-7 in mouse versus human cells.
PubMed ID: 17928527
PubMed ID: 18624290
Title: Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function.
PubMed ID: 18624290
PubMed ID: 18957693
Title: Essential role of DAP12 signaling in macrophage programming into a fusion-competent state.
PubMed ID: 18957693
PubMed ID: 19369195
Title: Large-scale proteomics analysis of the human kinome.
PubMed ID: 19369195
PubMed ID: 21727189
Title: The immunoreceptor adapter protein DAP12 suppresses B lymphocyte-driven adaptive immune responses.
PubMed ID: 21727189
DOI: 10.1084/jem.20101623
PubMed ID: 23715743
Title: DAP12 impacts trafficking and surface stability of killer immunoglobulin-like receptors on natural killer cells.
PubMed ID: 23715743
DOI: 10.1189/jlb.0213093
PubMed ID: 25957402
Title: DAP12 stabilizes the C-terminal fragment of the triggering receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-inflammatory response.
PubMed ID: 25957402
PubMed ID: 26221034
Title: Identification and Characterization of CD300H, a New Member of the Human CD300 Immunoreceptor Family.
PubMed ID: 26221034
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
PubMed ID: 26358190
Title: Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27.
PubMed ID: 26358190
DOI: 10.1038/cr.2015.108
PubMed ID: 20890284
Title: The structural basis for intramembrane assembly of an activating immunoreceptor complex.
PubMed ID: 20890284
DOI: 10.1038/ni.1943
PubMed ID: 25981043
Title: Transmembrane complexes of DAP12 crystallized in lipid membranes provide insights into control of oligomerization in immunoreceptor assembly.
PubMed ID: 25981043
PubMed ID: 27658901
Title: TYROBP genetic variants in early-onset Alzheimer's disease.
PubMed ID: 27658901
PubMed ID: 28716534
Title: Mutations in TYROBP are not a common cause of dementia in a Turkish cohort.
PubMed ID: 28716534
Sequence Information:
- Length: 113
- Mass: 12179
- Checksum: 267CB1C1756F89F0
- Sequence:
MGGLEPCSRL LLLPLLLAVS GLRPVQAQAQ SDCSCSTVSP GVLAGIVMGD LVLTVLIALA VYFLGRLVPR GRGAAEAATR KQRITETESP YQELQGQRSD VYSDLNTQRP YYK
Genular Protein ID: 177418576
Symbol: X6RGC9_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 11237011
Title: Initial sequencing and analysis of the human genome.
PubMed ID: 11237011
DOI: 10.1038/35057062
PubMed ID: 15057824
Title: The DNA sequence and biology of human chromosome 19.
PubMed ID: 15057824
DOI: 10.1038/nature02399
PubMed ID: 15496913
Title: Finishing the euchromatic sequence of the human genome.
PubMed ID: 15496913
DOI: 10.1038/nature03001
PubMed ID: 19369195
Title: Large-scale proteomics analysis of the human kinome.
PubMed ID: 19369195
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
Sequence Information:
- Length: 101
- Mass: 10972
- Checksum: 63633932D40DCC95
- Sequence:
MGGLEPCSRL LLLPLLLAVS DCSCSTVSPG VLAGIVMGDL VLTVLIALAV YFLGRLVPRG RGAAEATRKQ RITETESPYQ ELQGQRSDVY SDLNTQRPYY K